OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	484
Lymphatic propagation of α-synuclein	474
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	405
Brain stimulation aids walking after spinal injury	354
Reply to ‘Perils and pitfalls of near-death experience research’	338
ANA2025 marks important milestones for the ANA and NINDS	337
Genetic insights from Parkinson disease in African and African admixed populations	296
Neural cell state shifts and fate loss in ageing and age-related diseases	275
Nociceptive action of calcitonin gene-related peptide in the trigeminovascular system	259
Global synergistic actions to improve brain health for human development	236
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	218
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	206
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	195
Disease-specific modifications of tau protein	188
Continuous levodopa production by an artificial enzyme	185
TREM2 mediates phagocytosis in glioblastoma	183
SEQUINS — a new initiative to address disparities in neurology	175
Nir Giladi (1955–2024)	173
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	172
Spinal muscular atrophy treatment in utero	172
Gut macrophages involved in Parkinson disease pathogenesis	164
Mitochondrial DNA instability in Huntington disease	160
Imperatives and co-benefits of research into climate change and neurological disease	150
The role of the gut microbiota in multiple sclerosis	149
The Digitized Memory Clinic	144

The impact of rare genetic variants on Alzheimer disease	120
Psychosis-causing lesions mapped to a hippocampal circuit	120
Ultrasound lets gene therapy into the brain	117
Brain volume is associated with cognition in MS	116
Amyloid plaques: hotspots for microglial turnover	116
Challenges of combining multimodal data in assessment of people with traumatic brain injury	114
MRI-based deep learning for TLE diagnosis	106
The challenges of anti-tau therapeutics in Alzheimer disease	104
Motor neuron disease in Africa: a critical appraisal of the literature	102
The World Brain Health Forum: breaking silos for co-ordinated action	98
Gene therapy for seizures in focal cortical dysplasia	97
Diversity, equity and inclusion in neurology	94
First trials test targeting of α-synuclein for Parkinson disease	93
Implications of AD plasma and PET biomarker discordance	88
Precision neuroimmunology in multiple sclerosis — the horizon is near	87
Parkinson disease pathology can originate in the kidney	87
Author Correction: Viral pathogens increase risk of neurodegenerative disease	86
Neuroinflammation predicts cognitive decline in FTD	85
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	84
Management of freezing of gait — mechanism-based practical recommendations	81
Neurological care for LGBT+ people	77
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	76
Low-field MRI for equitable epilepsy diagnosis in resource-limited settings	74
α-Synuclein pathology as a target in neurodegenerative diseases	71
Chromosome 21 gene DSCAM drives Down syndrome phenotypes	71
Neurosteroids alleviate seizures in rats	70
Glymphatic dysfunction in PD clinical progression	68
Ultrasound ablation treatment for PD	65
Addressing disparities in neurology by building the workforce in LMICs	65
A new biological classification for Parkinson disease	65
Thalamic inflammation — a therapeutic target for brain injury?	63
Food is brain medicine — relevance and translation to neurology	61
Spinal cord stimulation for the treatment of chronic pain	60
Skull bone marrow changes in multiple sclerosis	60
Newborn screening for spinal muscular atrophy: time is motor neuron	59
Coeliac disease as a model for understanding multiple sclerosis	57
Brain-first and body-first subtypes of Lewy body disease	56
New IDEAS about amyloid, race and dementia disparities	54
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	54
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	54
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	52
Is Alzheimer disease a disease?	51
The global and regional burden of diabetic peripheral neuropathy	51
Synaptic degeneration in Alzheimer disease	51
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	48
X-chromosome variants and PD in Latin America	48
Neurofilament light chain induces neuroinflammation	48
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	48
Neurology in 2025 — reflections from Africa	48
Hypothyroidism is associated with dementia risk	48

Lorenzo’s House: shining a light on young-onset dementia	47
Oligomeric tau could spread through synapses in AD	46
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	41
The inter-relationship between delirium and dementia: the importance of delirium prevention	40
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	40
Global epidemiology of migraine and its implications for public health and health policy	40
Risk locus for paediatric astrocytoma identified	39
α-Synuclein seeds in amyotrophic lateral sclerosis	37
Moving towards meaningful patient and public engagement	37
Prognostic plasma biomarkers for spinal cord injury	35
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	35
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	34
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	34
Promoting collaboration at the brain–heart interface	34
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	34
Reply to ‘Recalled experiences of death: need for empirical research without prejudice’	33
CAR T cells offer hope in glioblastoma	33
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	32
Neurology in 2025 — reflections from the USA	32
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	30
Huntington disease-like 2: insight into neurodegeneration from an African disease	30
Christina Kim: functional and biochemical mapping of neural circuits	30
Dual function of biomolecular condensates	29
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	29
New developments in guidelines for brain death/death by neurological criteria	28
Psychological interventions for migraine	28
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	27
Understanding the long-term neurological effects of SARS-CoV-2 infection	27
Origins and immunopathogenesis of autoimmune central nervous system disorders	26
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	26
ALS pathogenesis linked to actin barrier collapse	25
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	25
Author Correction: The complex aetiology of cerebral palsy	25
Urogenital dysfunction in neurological diseases	23
Pharmacological rehabilitation for stroke	22
Serum NfL as an MS biomarker	22
Immune gateways bypass blood–brain barrier for drug delivery in stroke	22
AI aces diagnosis of chronic ataxias	22
AI and protein structure and function in neurological disease: relevance to disease management	22
The murky waters of sex differences in post-stroke cognitive impairment	20
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	20
BCAS1+ oligodendrocytes aid remyelination in MS	20
Pathogenetic mechanisms and treatment targets in cerebral malaria	19
Molecular biomarkers for vascular cognitive impairment and dementia	19
Addressing disparities in the global epidemiology of stroke	18
Effects of diet on MS onset and course	18
The potential of low-field MRI for global dementia care	18
Clocking the age of Parkinson disease onset	18
Altered muscle cholesterol transport in ALS	17
Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions	16
Predictive tools in psychosis: what is ‘good enough’?	16
Nanoprobe for blood–brain barrier changes	16
Advancing multiple sclerosis management in older adults	15
Alzheimer disease seen through the lens of sex and gender	15
Sex and gender in neurodevelopmental conditions	14
Mechanistic insights into the interaction between epilepsy and sleep	14
From adaptive deep brain stimulation to adaptive circuit targeting	14
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	14
Markers help to predict dementia with Lewy bodies	14
Multidimensional MRI detects astrogliosis	13
Limitations of neurocentric models for near-death experiences	13
Evidence-based clinical care and policy making for schizophrenia	13
Shared glial pathology in HD and schizophrenia	13
Author Correction: Why functional neurological disorder is not feigning or malingering	13
Alzheimer disease in Down syndrome linked to APOE	13
Walking the Talk for Dementia — an experience to break down barriers	13
Seizure-associated changes in the Golgi apparatus	13